Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
Executive Summary
Up-front spending on pharmaceuticals to treat colorectal cancer in the U.S. would be $7.5 bil. per year if oncologists use newly launched therapies without restrictions, Memorial-Sloan Kettering Cancer Center researcher Leonard Saltz, MD, told the American Society of Clinical Oncology annual meeting June 5 in New Orleans
You may also be interested in...
Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?
Amgen announced a program to limit patients' out-of-pocket cost for Vectibix, following FDA approval of panitumumab Sept. 27.
Amgen Vectibix Cap Cuts Patient Cost, But Will Payers Balk At High Price?
Amgen announced a program to limit patients' out-of-pocket cost for Vectibix, following FDA approval of panitumumab Sept. 27.
Initial Oncologic Prices Must Factor In Future Changes In Dosing – Bristol
Manufacturers should take into account potential differences in dosing for future indications when setting prices for novel oncologics, Bristol-Myers Squibb CFO Andrew Bonfield said June 15